While most CXCL10 antibodies are still in preclinical or early clinical development, they are also being investigated for inflammatory and autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease, where aberrant CXCL10 expression plays a pathogenic role. This evidence concerns the gene CXCL10 and multiple sclerosis.